Background: Bronchopulmonary dysplasia (BPD) is one of the main consequences of prematurity, with notably high heritability. Vascular endothelial growth factor A (VEGF-A) and its main receptor, vascular endothelial growth factor receptor 2 (VEGFR-2), have been implicated in the pathogenesis of BPD. Objective: To study whether common polymorphisms of the genes encoding VEGF-A and VEGFR-2 are associated with BPD. Methods: In this association study, six tagging single nucleotide polymorphism (tSNPs) for VEGFA and 25 tSNPs for VEGFR2 were genotyped in a prospectively collected, genetically homogeneous discovery population of 160 infants (44 infants with grade 2-3 BPD) born before 30 completed gestational weeks. The replication population of 328 infants included 120 cases of BPD. Results:VEGFR2 SNP rs4576072 was associated with BPD grade 2-3 with a minor allele frequency in 23.9% of the cases compared to 9.1% in controls (p = 0.0005, odds ratio 3.15, 95% CI: 1.62-6.12) in the discovery population. This association was not observed in the more heterogeneous replication population. Conclusions: In line with the results of recent large-scale genetic studies, our findings indicate that common polymorphisms of the genes encoding VEGF-A and VEGFR-2 are not consistently associated with BPD. This finding does not rule out the involvement of VEGFA and VEGFR2 in BPD pathogenesis since, in addition to common variations within the gene region, other mechanisms also play important roles in the regulation of gene function.

Keywords:
Preterm infant, Broncopulmonary dysplasia, Single nucleotide polymorphism, Association analysis
1.
Abman SH: Bronchopulmonary dysplasia: ‘a vascular hypothesis'. Am J Respir Crit Care Med 2001;164:1755-1756.
2.
Bhatt AJ, Amin SB, Chess PR, Watkins RH, Maniscalco WM: Expression of vascular endothelial growth factor and Flk-1 in developing and glucocorticoid-treated mouse lung. Pediatr Res 2000;47:606-613.
3.
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
4.
Simpson A, Custovic A, Tepper R, Graves P, Stern DA, Jones M, Hankinson J, Curtin JA, Wu J, Blekic M, Bukvic BK, Aberle N, Marinho S, Belgrave D, Morgan WJ, Martinez FD: Genetic variation in vascular endothelial growth factor-A and lung function. Am J Respir Crit Care Med 2012;185:1197-1204.
5.
An SJ, Chen ZH, Lin QX, Su J, Chen HJ, Lin JY, Wu YL: The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer. BMC Cancer 2009;9:144.
6.
Maniscalco WM, Watkins RH, Pryhuber GS, Bhatt A, Shea C, Huyck H: Angiogenic factors and alveolar vasculature: development and alterations by injury in very premature baboons. Am J Physiol Lung Cell Mol Physiol 2002;282:L811-L823.
7.
Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, Abman SH: Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L600-L607.
8.
Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH: Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 2002;283:L555-L562.
9.
Kunig AM, Balasubramaniam V, Markham NE, Morgan D, Montgomery G, Grover TR, Abman SH: Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. Am J Physiol Lung Cell Mol Physiol 2005;289:L529-L535.
10.
Thebaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, Hashimoto K, Harry G, Haromy A, Korbutt G, Archer SL: Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 2005;112:2477-2486.
11.
Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM: Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;164:1971-1980.
12.
Janer J, Andersson S, Haglund C, Karikoski R, Lassus P: Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development. Pediatrics 2008;122:340-346.
13.
Levesque BM, Kalish LA, Winston AB, Parad RB, Hernandez-Diaz S, Phillips M, Zolit A, Morey J, Gupta M, Mammoto A, Ingber DE, Van Marter LJ: Low urine vascular endothelial growth factor levels are associated with mechanical ventilation, bronchopulmonary dysplasia and retinopathy of prematurity. Neonatology 2013;104:56-64.
14.
Bhandari V, Bizzarro MJ, Shetty A, Zhong X, Page GP, Zhang H, Ment LR, Gruen JR; Neonatal Genetics Study Group: Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 2006;117:1901-1906.
15.
Lavoie PM, Pham C, Jang KL: Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. Pediatrics 2008;122:479-485.
16.
Jobe AH, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-1729.
17.
Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G, Auten K, Newman N, Rowan G, Grisby C, Arnell K, Miller L, Ball B, McDavid G; National Institute of Child Health and Human Development Neonatal Research Network: Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004;114:1305-1311.
18.
Soudee S, Vuillemin L, Alberti C, Mohamed D, Becquet O, Farnoux C, Biran V, Baud O: Fetal growth restriction is worse than extreme prematurity for the developing lung. Neonatology 2014;106:304-310.
19.
Jakkula E, Rehnstrom K, Varilo T, Pietilainen OP, Paunio T, Pedersen NL, deFaire U, Jarvelin MR, Saharinen J, Freimer N, Ripatti S, Purcell S, Collins A, Daly MJ, Palotie A, Peltonen L: The genome-wide patterns of variation expose significant substructure in a founder population. Am J Hum Genet 2008;83:787-794.
20.
Hadchouel A, Durrmeyer X, Bouzigon E, Incitti R, Huusko J, Jarreau PH, Lenclen R, Demenais F, Franco-Montoya ML, Layouni I, Patkai J, Bourbon J, Hallman M, Danan C, Delacourt C: Identification of SPOCK2 as a susceptibility gene for bronchopulmonary dysplasia. Am J Respir Crit Care Med 2011;184:1164-1170.
21.
Wang H, St Julien KR, Stevenson DK, Hoffmann TJ, Witte JS, Lazzeroni LC, Krasnow MA, Quaintance CC, Oehlert JW, Jelliffe-Pawlowski LL, Gould JB, Shaw GM, O'Brodovich HM: A genome-wide association study (GWAS) for bronchopulmonary dysplasia. Pediatrics 2013;132:290-297.
22.
Ambalavanan N, Cotten CM, Page GP, Carlo WA, Murray JC, Bhattacharya S, Mariani TJ, Cuna AC, Faye-Petersen OM, Kelly D, Higgins RD; Genomics and Cytokine Subcommittees of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network: Integrated genomic analyses in bronchopulmonary dysplasia. J Pediatr 2015;166:531-537.e13.
23.
Bhattacharya S, Go D, Krenitsky DL, Huyck HL, Solleti SK, Lunger VA, Metlay L, Srisuma S, Wert SE, Mariani TJ, Pryhuber GS: Genome-wide transcriptional profiling reveals connective tissue mast cell accumulation in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2012;186:349-358.
24.
Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Legutko M, Pietrzyk JJ: Genetic risk factors of bronchopulmonary dysplasia. Pediatr Res 2008;64:682-688.
25.
Banyasz I, Bokodi G, Vasarhelyi B, Treszl A, Derzbach L, Szabo A, Tulassay T, Vannay A: Genetic polymorphisms for vascular endothelial growth factor in perinatal complications. Eur Cytokine Netw 2006;17:266-270.
26.
Mailaparambil B, Krueger M, Heizmann U, Schlegel K, Heinze J, Heinzmann A: Genetic and epidemiological risk factors in the development of bronchopulmonary dysplasia. Dis Markers 2010;29:1-9.
27.
Floros J, Londono D, Gordon D, Silveyra P, Diangelo SL, Viscardi RM, Worthen GS, Shenberger J, Wang G, Lin Z, Thomas NJ: IL-18R1 and IL-18RAP SNPs may be associated with bronchopulmonary dysplasia in African-American infants. Pediatr Res 2012;71:107-114.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.